ISRCTN92868457已完成2 期
Phase II study of combination therapy with 5-AZAcytidine, Valproic acid, and All-Trans Retinoic Acid in patients with myelodysplastic syndromes and other myeloid malignancies who cannot receive intensive chemotherapy
Heinrich-Heine-University (Germany)0 个研究点目标入组 24 人开始时间: 2007年7月19日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Primary Myelodysplastic Syndromes (pMDS) with unfavourable risk profile (more than 10% blast cells in the bone marrow, unfavourable karyotype)
- •2. Therapy-related (secondary) Myelodysplastic Syndromes (sMDS)
- •3. Chronic Myelomonocytic Leukaemia (CMML)
- •4. De-novo or secondary acute myeloid leukemia in elderly patients who cannot be treated with intensive chemotherapy
排除标准
- •1. Impaired liver or kidney function
- •2. Pregnancy
- •3. Simultaneous participation in another clinical trial
研究者
相似试验
进行中（未招募）
1 期
Comparison between 5 – azacytidine treatment and 5 – azacytidine followed by allogeneic stem cell transplantation in elderly patients with advanced MDS according to donor availabilityEUCTR2010-018467-42-DEniversity Medical Center Hamburg-Eppendorf110
进行中（未招募）
1 期
Administration of 5-azacytidine and lymphocytes in patients in relapse after treatment by transplantation for a hematological cancer.Acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) in relapse after allogeneic stem cell transplantationMedDRA version: 18.0 Level: PT Classification code 10059034 Term: Acute myeloid leukaemia recurrent System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.0 Level: HLT Classification code 10028536 Term: Myelodysplastic syndromes System Organ Class: 100000004851EUCTR2012-005535-90-BECHU Mont-Godinne50
进行中（未招募）
1 期
Phase ll Study of the Adjunctive Use of Azacitidine in Patients Undergoing Reduced Intensity Allogeneic Transplantation for Acute Myeloid Leukaemia - RICAZAEUCTR2007-006475-36-GBniversity of Birmingham40
进行中（未招募）
不适用
A Randomised Phase II trial of 5-Azacitidine versus 5-Azacitidine in combination with Vorinostat in patients with relapsed Acute Myeloid Leukaemia ineligible for intensive chemotherapyEUCTR2011-005207-32-GBThe University of Birmingham
进行中（未招募）
1 期
Pilot study of 5 Azacitidine in the treatment of MDS/AML with high risk (chromosome 7 and/or complex cytogenetic abnormality) - Azacitidine for MDS with high risk cytogeneticsmyelodysplastic syndromes/relapsed Acute myeloid leukaemiaEUCTR2005-003732-22-GBKings College London43